AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00685035 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HFCWC with lower pressure/mid-frequency settings
Description: Subjects will perform pulmonary function tests prior to and following each airway clearance therapy. All sputum produced during, and for 15 minutes following airway clearance therapy will be collected. Subjects will complete a questionnaire addressing the comfort of therapy upon completion of the session.
Study NCT00493792 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: X3 Polyethylene
Description: Highly cross-linked polyethylene (HXLPE).
Study NCT00493792 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: N2Vac Polyethylene
Description: Ultra-high-molecular-weight polyethylene (UHMWPE).
Study NCT02136238 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hosmer 5XA voluntary opening hook
Description: Voluntary opening prosthetic terminal device (hand)
Study NCT02136238 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TRS Grip 3 voluntary closing hook
Description: Voluntary closing prosthetic terminal device (hand)
Study NCT02354807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: One-time dose of 100mg of Mirabegron
Study NCT03402646 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder module (SMS and Phone call)
Description: Same as described under arm/group descriptions
Study NCT03402646 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Photovoice
Description: Same as described under arm/group descriptions
Study NCT01931592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ESBL eradication regimen
Description: Fosfomycin-trometamol (3 g granules dissolved in 200 ml of water for oral administration every 72h) and colistin (2x106 IU oral solution dissolved in 50-100 ml of water given orally every 6 hours) and gentamicin (an 80 mg oral solution dissolved in 50-100 ml of water given orally every 6 hours) will be administered in a double-blind fashion for a total duration of 7 days (day 1-7). The placebo treatment will be identical in taste, consistency, colour and packaging. To include the oral cavity into the eradication regimen, all medications should be gargled for at least 10 seconds before being swallowed.
Study NCT01931592 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ESBL eradication
Description: Placebo preparations of fosfomycin, gentamicin and colisitin, identical in taste, texture and color will be administered at the same rate as the active comparator medication.
Study NCT02336373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyurea
Description: Treat symptomatic HbSC patients to MTD on hydroxyurea, and assess for clinical improvement using the PedsQL™ Sickle Cell Disease Module version 3.0 after 6 months at MTD, compared to entrance scores
Study NCT03145233 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric exercise programme
Description: Exercise programme where the muscle length and joint angle do not change due to the limb being held in a static position
Study NCT03145233 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isotonic exercise programme
Description: Exercise programme where both the muscle length and joint angle do change, consisting of concentric muscle actions (where the muscle shortens) and eccentric muscle actions (where the muscle lengthens)
Study NCT02436304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXE844 Sterile Otic Suspension, 0.3%
Study NCT02436304 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tympanostomy Tube Insertion
Description: Surgical procedure for treating pediatric cases of recurrent or chronic otitis media
Study NCT02436304 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tympanostomy Tube Insertion
Description: Surgical procedure for treating pediatric cases of recurrent or chronic otitis media
Study NCT00257465 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous, DNP-modified vaccine (M-Vax)
Description: 5.0, 2.5, 0.5, or 0 cells
Study NCT00257465 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous, DNP-Modified Melanoma Vaccine
Description: 5 million cells
Study NCT00257465 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous, DNP-Modified Vaccine
Description: 2.5 million cells
Study NCT00257465 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous, DNP-Modified Vaccine
Description: 0.5 million cells
Study NCT00257465 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Autologous, DNP-Modified Vaccine
Description: 0 cells
Study NCT04168697 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wim Hof method
Description: 8-week behavioral modification intervention instructing the participants in a combination of breathing exercises, cold exposure and meditation
Study NCT02400229 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed tomography angiography (cardiac CT)
Description: Clinical management/treatment decisions based on cardiac computed tomography including coronary calcium scoring and coronary computed tomography angiography
Study NCT02400229 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Invasive coronary angiography (ICA)
Description: Clinical management/treatment decisions based on invasive coronary angiography
Study NCT00532324 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CA-MRSA Decolonization
Description: In later stages of this study, women found to be nasally and/or vaginally colonized with CA-MRSA will be randomized to receive postpartum, either: 1) attempted decolonization with intranasal mupirocin twice a day for one to two weeks with or without diluted chlorhexidine or Clorox baths two to three times a week for one to two weeks or, 2) no intervention. The primary study is observational only.
Study NCT03921073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-VEC
Description: Participants will receive intralesional injections of T-VEC of up to 4cc. Dosing of T-VEC is dependent of the size of the lesion.
Study NCT01349088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Patients will receive ixabepilone at 40 mg/m2.
Study NCT00699686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine
Description: Daily bedtime subcutaneous insulin Glargine in individualized doses.
Study NCT00699686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Detemir
Description: Daily bedtime subcutaneous insulin Detemir in individualized doses.
Study NCT03199417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiprofen
Description: A multimodal topical cream treatment with Ketoprofen, Baclofen, Amitryptiline, and lidocaine in a carrier gel.
Study NCT02354807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold exposure
Description: Exposure of subjects to cold temperature to induce non-shivering thermogenesis
Study NCT01940263 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Anthocyanin
Study NCT03199417 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An identically packaged placebo cream
Study NCT05349604 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One intake in total
Study NCT01889251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocriplasmin
Study NCT01889251 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Study NCT03923101 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Topographic, tomographic and biomechanical analysis.
Description: The study is based upon data obtained during routine medical follow-ups using~1. the Pentacam high resolution (Oculus, Wetzlar, Germany)~2. the Corvis ST (Oculus, Wetzlar, Germany)~3. the Anterior-Segment Optical Coherence Tomograph (AS-OCT) Casia 2 (Tomey, Nagoya, Japan)~4. the Ocular Response Analyzer (Reichert Technologies, New York, USA).
Study NCT06692478 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise regimen
Description: Age 4-6 years: Target lower extremity, core and upper extremity strengthening and activity tolerance. With supervision by the PT, the patient will walk in their room, and complete the following through play: squat, single leg stance, climb onto couch, half kneel to stand, quadruped and tall kneeling.~Age 7-21 years: First component will be strengthening exercises completed in bed or on a mat while sitting or standing. Multiple levels of exercises will be available, so that the program can be tailored to each patient and to their ability to perform activities. The exercises included will focus on core, hip musculature, and upper extremity strengthening; including exercises in quadruped and prone positioning, as well as supine, sitting and standing. Thera-Band will be used to increase resistance as needed. The second component will be endurance. Since the patients will be confined to their room this will include ambulation within the room, recumbent or pedal exerciser and step ups.
Study NCT03006341 — intervention group
Intervention type: DRUG
Intervention: Dabigatran etexilate
Description: observed upto 12 months
Study NCT03006341 — intervention group
Intervention type: DRUG
Intervention: Warfarin
Description: Observed upto 12 months
Study NCT01695317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetyl-L-carnitine
Description: Week 1: 500 mg x 3, Week 2-12: 500 mg x 6
Study NCT01940263 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01695317 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetyl-L-carnitine
Description: Week 1: 500 mg x 3, Week 2-12: 500 mg x 6
Study NCT01501435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-30039
Description: single dose
Study NCT01501435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fenofibric acid
Description: single dose
Study NCT02148406 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Skills Training (YST)
Description: Undergo YST
Study NCT02148406 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT02148406 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT02148406 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fatigue and depressive symptom assessment and management
Description: Ancillary studies
Study NCT02148406 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fatigue and depressive symptom assessment and management
Description: Ancillary studies
Study NCT02148406 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychological stress assessment
Description: Ancillary studies
Study NCT02148406 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: psychological stress assessment
Description: Ancillary studies
Study NCT02148406 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02148406 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02148406 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Study NCT00003656 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa
Study NCT00392574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prulifloxacin
Description: Tablet
Study NCT00003656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tretinoin liposome
Study NCT00825435 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary CT Angiogram
Description: Coronary CT Angiogram
Study NCT02685280 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Restore Advanced 37713
Description: Rechargeable neurostimulators are implanted when the non-rechargeable neurostimulators are end-of-life.
Study NCT01428895 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery Alone
Description: Although we are looking at two groups, this intervention is not protocol specific but is part of the patient's standard management plan. The protocol specific part of the study is completely observational. This involves data being recorded by the attending physician during assessment and patient accounts recorded in the form of questionnaires.
Study NCT01428895 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined Surgery and Radiation therapy
Description: Although we are looking at two groups, this intervention is not protocol specific but is part of the patient's standard management plan. The protocol specific part of the study is completely observational. This involves data being recorded by the attending physician during assessment and patient accounts recorded in the form of questionnaires.
Study NCT00692562 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: simultaneous islet-kidney transplantation
Study NCT01341678 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lanthanum Carbonate
Description: Diet will be supplemented with 1000mg at each meal
Study NCT01341678 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: NeutraPhos
Description: Diet will be supplemented with NeutraPhos
Study NCT01341678 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diet Only
Description: Diet containing 1500mg of phosphorus
Study NCT01486108 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dorsal column stimulator
Description: test different settings of stimulation
Study NCT00760786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intensive lipid lowering plus Omega3-fatty acid
Description: Atorvastatin 40mg qd plus Omega3-fatty acid 2.0mg qd
Study NCT00760786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moderate lipid lowering plus Omega3-fatty acid
Description: atorvastatin 10mg qd plus Omega3-fatty acid 2.0mg qd
Study NCT00760786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intensive lipid lowering plus placebo
Description: atorvastatin 40mg qd
Study NCT00760786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moderate lipid lowering plus placebo
Description: atorvastatin 10mg qd
Study NCT03671187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 8 week exercise program
Study NCT02237547 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous and intrathecal human umbilical cord tissue-derived mesenchymal stem cells and bone marrow mononuclear cells
Study NCT02770144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Coaching
Description: Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
Study NCT00392574 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet
Study NCT02276040 — intervention group
Intervention type: DRUG
Intervention: periarticular bupivicaine and liposomal bupivicaine
Description: Participants will receive Exparel (liposomal bupivacaine). Exparel is a FDA approved product. Exparel is an extended-release formulation of bupivacaine consisting of microscopic lipid-based particles that diffuse over an extended period. The result is pain relief that can last up to 96 hours after surgery. Extended-release liposomal bupivacaine-based analgesics were shown to provide extended pain relief and decrease opioid (pain medication) use. At the conclusion of the total joint arthroplasty procedure, Exparel is administered via injection into the joint (periarticular bupivicaine and liposomal bupivicaine).
Study NCT02474173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02474173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onalespib
Description: Given IV
Study NCT02474173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT02474173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02568319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIPO-202
Study NCT02568319 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02567903 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thigh Tourniquet
Description: Knee arthroscopy with the use of a thigh tourniquet that is inflated to 100-150 mmHg above systolic blood pressure.
Study NCT02567903 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Knee arthroscopy
Description: Knee arthroscopy
Study NCT02567903 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Knee arthroscopy
Description: Knee arthroscopy
Study NCT04386746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1g gemcitabine in 50ml sterile water; instilled once weekly for 6 weeks and then once monthly for ≤ 21 months.
Study NCT04386746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 37.5mg docetaxel in 50ml normal saline solution (NSS); instilled once weekly for 6 weeks and then once monthly for ≤ 21 months.
Study NCT02703727 — intervention group
Intervention type: BEHAVIORAL
Intervention: Extended polymedication check
Description: Behavioral: Medication review~Patients on oral anticoagulants and polypharmacy will receive extended polymedication check to identify Pharmaceutical Care Issues, Adherence Issues, Drug related problems and Knowledge Gaps~The PMC has been implemented in 2010 as a new cognitive service provided by any community pharmacist to patient with polypharmacy (n>3 drugs) on long term conditions (> 3 months) and is reimbursed by swiss health insurance. The semi-structured interview contains questions about knowledge on oral anticoagulation therapy. This extended PMC follows a structured predefined protocol.~As an outcome, pharmacist may install a compliance support e.g. weekly filled pill organizer.
Study NCT04765943 — intervention group
Intervention type: DEVICE
Intervention: Implantable Loop Recorder implant
Description: Patients will be undergone to an Implantable Loop Recorder implant and monitored for the next 6 months.They will then undergo a cardiac MRI and an ICD will be implanted according to clinical practice guidelines. A minimum follow-up of 2 years is scheduled.
Study NCT02276131 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vigilant Diabetes Management Application
Description: Human factors and usability assessment of the device in the hands of diabetes subjects and caregivers
Study NCT03916926 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A simple medical strategy consisting of silver diamine fluoride (SDF)
Description: Advantage Arrest, Elevate Oral Care LLC., West Palm Beach, FL)
Study NCT03916926 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: B typical dental strategy consisting of atraumatic restorative treatment (ART) with glass ionomer cement + Fluoride varnish (FV)
Description: GC Fuji (for ART) and FluoriMax Advantage Arrest, Elevate Oral Care LLC., West Palm Beach, FL (for FV)
Study NCT04208737 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: recruitment maneuver
Description: 30 cmH2O pressure 15 seconds
Study NCT02047461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORGN001 (formerly ALXN1101)
Description: IV infusion
Study NCT03270930 — intervention group
Intervention type: PROCEDURE
Intervention: Emergency laparotomy
Description: All patients in study underwent emergency laparotomy within 24 hours of presentation after adequate resuscitation of minimum 1 hour.
Study NCT01971918 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti drug antibodies dosage
Description: anti drug antibodies dosage
Study NCT03828695 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: uterocervical angle
Description: uterocervical angle is the angle between lower segment of uterus and cervix
Study NCT04109690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: Patients in both Phase I and II can receive a maximum of two induction and six consolidation cycles on an inpatient or outpatient basis per local hospital standard of care.
Study NCT02892799 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NICOM-Guided Diuresis
Description: NICOM-based assessment of PLR-induced change in cardiac index
Study NCT02892799 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Study NCT00466791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate Transdermal System
Description: Placebo
Study NCT00466791 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylphenidate Transdermal System
Description: Placebo
Study NCT03365609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triple therapy
Description: Omeprazole+Amoxicillin+Clarithromycin
Study NCT03365609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sequential therapy
Description: the first 7 days : Omeprazole+Amoxicillin, the last 7 days: Omeprazole+Clarithromycin+Metronidazole
Study NCT03365609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bismuth quadruple therapy
Description: Omeprazole+Amoxicillin+Metronidazole+Colloidal Bismuth Subcitrate